Literature DB >> 24337744

Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.

Nolan K Maier1, Devorah Crown, Jie Liu, Stephen H Leppla, Mahtab Moayeri.   

Abstract

Inflammasomes are large cytoplasmic multiprotein complexes that activate caspase-1 in response to diverse intracellular danger signals. Inflammasome components termed nucleotide-binding oligomerization domain-like receptor (NLR) proteins act as sensors for pathogen-associated molecular patterns, stress, or danger stimuli. We discovered that arsenicals, including arsenic trioxide and sodium arsenite, inhibited activation of the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes by their respective activating signals, anthrax lethal toxin, nigericin, and flagellin. These compounds prevented the autoproteolytic activation of caspase-1 and the processing and secretion of IL-1β from macrophages. Inhibition was independent of protein synthesis induction, proteasome-mediated protein breakdown, or kinase signaling pathways. Arsenic trioxide and sodium arsenite did not directly modify or inhibit the activity of preactivated recombinant caspase-1. Rather, they induced a cellular state inhibitory to both the autoproteolytic and substrate cleavage activities of caspase-1, which was reversed by the reactive oxygen species scavenger N-acetylcysteine but not by reducing agents or NO pathway inhibitors. Arsenicals provided protection against NLRP1-dependent anthrax lethal toxin-mediated cell death and prevented NLRP3-dependent neutrophil recruitment in a monosodium urate crystal inflammatory murine peritonitis model. These findings suggest a novel role in inhibition of the innate immune response for arsenical compounds that have been used as therapeutics for a few hundred years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337744      PMCID: PMC3884817          DOI: 10.4049/jimmunol.1301434

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.

Authors:  Dennis A Carney
Journal:  Leuk Lymphoma       Date:  2008-10

2.  Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.

Authors:  Yu-Hsun Lo; Yu-Wen Huang; Yung-Hsuan Wu; Chi-Shan Tsai; Yu-Chuan Lin; Shu-Ting Mo; Wen-Chih Kuo; Ya-Ting Chuang; Si-Tse Jiang; Hsiu-Ming Shih; Ming-Zong Lai
Journal:  Blood       Date:  2013-02-21       Impact factor: 22.113

Review 3.  Inflammasomes in carcinogenesis and anticancer immune responses.

Authors:  Laurence Zitvogel; Oliver Kepp; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Immunol       Date:  2012-03-18       Impact factor: 25.606

Review 4.  Curing APL through PML/RARA degradation by As2O3.

Authors:  Valerie Lallemand-Breitenbach; Jun Zhu; Zhu Chen; Hugues de Thé
Journal:  Trends Mol Med       Date:  2011-11-04       Impact factor: 11.951

5.  Optimized production and purification of Bacillus anthracis lethal factor.

Authors:  S Park; S H Leppla
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

Review 6.  Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics.

Authors:  Jodi E Goldberg; Kathryn L Schwertfeger
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

Review 7.  How acute promyelocytic leukaemia revived arsenic.

Authors:  Jun Zhu; Zhu Chen; Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 8.  Inflammasome and IL-1beta-mediated disorders.

Authors:  Hal M Hoffman; Alan A Wanderer
Journal:  Curr Allergy Asthma Rep       Date:  2010-07       Impact factor: 4.806

9.  Susceptibility to anthrax lethal toxin-induced rat death is controlled by a single chromosome 10 locus that includes rNlrp1.

Authors:  Zachary L Newman; Morton P Printz; Shihui Liu; Devorah Crown; Laura Breen; Sharmina Miller-Randolph; Pamela Flodman; Stephen H Leppla; Mahtab Moayeri
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

10.  Sodium arsenite induces heat shock protein 70 expression and protects against secretagogue-induced trypsinogen and NF-kappaB activation.

Authors:  Lakshmi Bhagat; Vijay P Singh; Rajinder K Dawra; Ashok K Saluja
Journal:  J Cell Physiol       Date:  2008-04       Impact factor: 6.384

View more
  19 in total

Review 1.  Double-Sided Personality: Effects of Arsenic Trioxide on Inflammation.

Authors:  Juan Zhang; Yue Zhang; Weiyan Wang; Chunling Li; Zhiyi Zhang
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 2.  Inflammasomes, the eye and anti-inflammasome therapy.

Authors:  P Yerramothu; A K Vijay; M D P Willcox
Journal:  Eye (Lond)       Date:  2017-11-24       Impact factor: 3.775

Review 3.  Old dog, new trick: Trivalent arsenic as an immunomodulatory drug.

Authors:  Yishan Ye; Béatrice Gaugler; Mohamad Mohty; Florent Malard
Journal:  Br J Pharmacol       Date:  2020-03-12       Impact factor: 8.739

Review 4.  Inflammasome inhibition under physiological and pharmacological conditions.

Authors:  Emily A Caseley; James A Poulter; François Rodrigues; Michael F McDermott
Journal:  Genes Immun       Date:  2020-07-17       Impact factor: 2.676

5.  The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes.

Authors:  Nolan K Maier; Stephen H Leppla; Mahtab Moayeri
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

Review 6.  NLRs as Helpline in the Brain: Mechanisms and Therapeutic Implications.

Authors:  Shalini Singh; Sushmita Jha
Journal:  Mol Neurobiol       Date:  2018-03-06       Impact factor: 5.590

7.  Elevated autoimmunity in residents living near abandoned uranium mine sites on the Navajo Nation.

Authors:  Esther Erdei; Chris Shuey; Bernadette Pacheco; Miranda Cajero; Johnnye Lewis; Robert L Rubin
Journal:  J Autoimmun       Date:  2019-03-14       Impact factor: 7.094

Review 8.  Pyroptosis and pyroptosis-inducing cancer drugs.

Authors:  Fan Yang; Sahana N Bettadapura; Mark S Smeltzer; Hua Zhu; Shanzhi Wang
Journal:  Acta Pharmacol Sin       Date:  2022-03-14       Impact factor: 7.169

9.  Activating transcription factor 4 underlies the pathogenesis of arsenic trioxide-mediated impairment of macrophage innate immune functions.

Authors:  Ritesh K Srivastava; Changzhao Li; Yong Wang; Zhiping Weng; Craig A Elmets; Kevin S Harrod; Jessy S Deshane; Mohammad Athar
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-25       Impact factor: 4.219

10.  Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism.

Authors:  Allison J Greaney; Nolan K Maier; Stephen H Leppla; Mahtab Moayeri
Journal:  J Leukoc Biol       Date:  2015-08-12       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.